Biomimetic Proteoglycans for Intervertebral Disc (IVD) Regeneration

Intervertebral disc degeneration, which leads to low back pain, is the most prevalent musculoskeletal condition worldwide, significantly impairing quality of life and imposing substantial socioeconomic burdens on affected individuals. A major impediment to the development of any prospective cell-dri...

Full description

Bibliographic Details
Main Authors: Neha Chopra, James Melrose, Zi Gu, Ashish D. Diwan
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Biomimetics
Subjects:
Online Access:https://www.mdpi.com/2313-7673/9/12/722
_version_ 1826917905532452864
author Neha Chopra
James Melrose
Zi Gu
Ashish D. Diwan
author_facet Neha Chopra
James Melrose
Zi Gu
Ashish D. Diwan
author_sort Neha Chopra
collection DOAJ
description Intervertebral disc degeneration, which leads to low back pain, is the most prevalent musculoskeletal condition worldwide, significantly impairing quality of life and imposing substantial socioeconomic burdens on affected individuals. A major impediment to the development of any prospective cell-driven recovery of functional properties in degenerate IVDs is the diminishing IVD cell numbers and viability with ageing which cannot sustain such a recovery process. However, if IVD proteoglycan levels, a major functional component, can be replenished through an orthobiological process which does not rely on cellular or nutritional input, then this may be an effective strategy for the re-attainment of IVD mechanical properties. Furthermore, biomimetic proteoglycans (PGs) represent an established polymer that strengthens osteoarthritis cartilage and improves its biomechanical properties, actively promoting biological repair processes. Biomimetic PGs have superior water imbibing properties compared to native aggrecan and are more resistant to proteolytic degradation, increasing their biological half-life in cartilaginous tissues. Methods have also now been developed to chemically edit the structure of biomimetic proteoglycans, allowing for the incorporation of bioactive peptide modules and equipping biomimetic proteoglycans as delivery vehicles for drugs and growth factors, further improving their biotherapeutic credentials. This article aims to provide a comprehensive overview of prospective orthobiological strategies that leverage engineered proteoglycans, paving the way for novel therapeutic interventions in IVD degeneration and ultimately enhancing patient outcomes.
first_indexed 2025-02-17T12:40:03Z
format Article
id doaj.art-4ce6365079c64ec6a13a92a95f0497cc
institution Directory Open Access Journal
issn 2313-7673
language English
last_indexed 2025-02-17T12:40:03Z
publishDate 2024-11-01
publisher MDPI AG
record_format Article
series Biomimetics
spelling doaj.art-4ce6365079c64ec6a13a92a95f0497cc2024-12-27T14:13:22ZengMDPI AGBiomimetics2313-76732024-11-0191272210.3390/biomimetics9120722Biomimetic Proteoglycans for Intervertebral Disc (IVD) RegenerationNeha Chopra0James Melrose1Zi Gu2Ashish D. Diwan3Spine Service & Spine Labs, St George & Sutherland School of Clinical Medicine, Faculty of Health and Medicine, University of New South Wales, Kogarah, NSW 2217, AustraliaGraduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052, AustraliaNanoBiotechnology Research Group, School of Chemical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW 2052, AustraliaSpine Service & Spine Labs, St George & Sutherland School of Clinical Medicine, Faculty of Health and Medicine, University of New South Wales, Kogarah, NSW 2217, AustraliaIntervertebral disc degeneration, which leads to low back pain, is the most prevalent musculoskeletal condition worldwide, significantly impairing quality of life and imposing substantial socioeconomic burdens on affected individuals. A major impediment to the development of any prospective cell-driven recovery of functional properties in degenerate IVDs is the diminishing IVD cell numbers and viability with ageing which cannot sustain such a recovery process. However, if IVD proteoglycan levels, a major functional component, can be replenished through an orthobiological process which does not rely on cellular or nutritional input, then this may be an effective strategy for the re-attainment of IVD mechanical properties. Furthermore, biomimetic proteoglycans (PGs) represent an established polymer that strengthens osteoarthritis cartilage and improves its biomechanical properties, actively promoting biological repair processes. Biomimetic PGs have superior water imbibing properties compared to native aggrecan and are more resistant to proteolytic degradation, increasing their biological half-life in cartilaginous tissues. Methods have also now been developed to chemically edit the structure of biomimetic proteoglycans, allowing for the incorporation of bioactive peptide modules and equipping biomimetic proteoglycans as delivery vehicles for drugs and growth factors, further improving their biotherapeutic credentials. This article aims to provide a comprehensive overview of prospective orthobiological strategies that leverage engineered proteoglycans, paving the way for novel therapeutic interventions in IVD degeneration and ultimately enhancing patient outcomes.https://www.mdpi.com/2313-7673/9/12/722biomimetic proteoglycansintervertebral discaggrecan
spellingShingle Neha Chopra
James Melrose
Zi Gu
Ashish D. Diwan
Biomimetic Proteoglycans for Intervertebral Disc (IVD) Regeneration
Biomimetics
biomimetic proteoglycans
intervertebral disc
aggrecan
title Biomimetic Proteoglycans for Intervertebral Disc (IVD) Regeneration
title_full Biomimetic Proteoglycans for Intervertebral Disc (IVD) Regeneration
title_fullStr Biomimetic Proteoglycans for Intervertebral Disc (IVD) Regeneration
title_full_unstemmed Biomimetic Proteoglycans for Intervertebral Disc (IVD) Regeneration
title_short Biomimetic Proteoglycans for Intervertebral Disc (IVD) Regeneration
title_sort biomimetic proteoglycans for intervertebral disc ivd regeneration
topic biomimetic proteoglycans
intervertebral disc
aggrecan
url https://www.mdpi.com/2313-7673/9/12/722
work_keys_str_mv AT nehachopra biomimeticproteoglycansforintervertebraldiscivdregeneration
AT jamesmelrose biomimeticproteoglycansforintervertebraldiscivdregeneration
AT zigu biomimeticproteoglycansforintervertebraldiscivdregeneration
AT ashishddiwan biomimeticproteoglycansforintervertebraldiscivdregeneration